Fig. 4.
Mean (SE) at baseline, last on-treatment visit with available assessment (LV [last non-missing value in Part B]), and at the 9-week early termination/safety follow-up (ET/SFU) in patients with CAD. a) haemoglobin; b) bilirubina,b; and c) Wieslab-CP activity. aBilirubin data excludes subjects with positive or unknown Gilbert's syndrome test result; bThe central laboratory normal range for bilirubin was 5.1–20.5 μmol/L. CAD, cold agglutinin disease. CP, complement pathway. ET/SFU, study follow-up visit 9 weeks after the last dose of sutimlimab. LV, last on-treatment visit with available assessment. SE, standard error. ULN, upper limit of normal.